Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Teva Pharmaceutical Industries Ltd (TEVA)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
[[ ctrl.chartTitle ]]
Full Chart

Fundamentals

See More
  • Market Capitalization, $K 33,098,824
  • Shares Outstanding, K 1,014,990
  • Annual Sales, $ 21,903 M
  • Annual Income, $ 329,000 K
  • 36-Month Beta 0.49
  • Price/Sales 1.51
  • Price/Cash Flow 4.93
  • Price/Book 1.03

Price Performance

See More
Period Period Low Period High Performance
1-Month
27.59 +19.32%
on 05/31/17
33.41 -1.47%
on 06/26/17
+4.42 (+15.51%)
since 05/26/17
3-Month
27.59 +19.32%
on 05/31/17
33.41 -1.47%
on 06/26/17
-0.11 (-0.33%)
since 03/27/17
52-Week
27.59 +19.32%
on 05/31/17
56.44 -41.67%
on 07/13/16
-15.61 (-32.17%)
since 06/27/16

Most Recent Stories

More News
Teva and Xenon Announce Phase II Study of Topical TV-45070 in Patients with Post-Herpetic Neuralgia (PHN) Did Not Meet Primary Endpoint

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) (TASE:TEVA) and Xenon Pharmaceuticals Inc. (Nasdaq:XENE) announce top-line results in a Phase II study of topical TV-45070 in patients with post-herpetic...

TEVA : 32.84 (-0.33%)
XENE : 3.00 (-21.05%)
Teva and Xenon Announce Phase II Study of Topical TV-45070 in Patients with Post-Herpetic Neuralgia (PHN) Did Not Meet Primary Endpoint

Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) and Xenon Pharmaceuticals Inc. (Nasdaq: XENE) announce top-line results in a Phase II study of topical TV-45070 in patients with...

TEVA : 32.84 (-0.33%)
XENE : 3.00 (-21.05%)
Allergan Continues to Focus on Acquisitions and Branded Unit

We issued an updated research report on Allergan plc (AGN) on Jun 23.

AGN : 249.03 (+0.05%)
TEVA : 32.84 (-0.33%)
RHHBY : 32.6400 (+0.52%)
AMGN : 173.61 (-0.03%)
Today's Research Reports on Stocks to Watch: Geron Corporation and Teva Pharmaceutical

NEW YORK, NY / ACCESSWIRE / June 23, 2017 / It was a disappointing day for Teva Pharmaceutical Industries on Thursday, but judging by the gains the stock saw yesterday nobody would have known it. The...

GERN : 2.91 (-1.02%)
TEVA : 32.84 (-0.33%)
GSK : 43.97 (-0.23%)
Global Chronic Kidney Disease (CKD) Drugs Market to Reach $17.4 Billion by 2025 - Analysis By Drug Class & Geography

Research and Markets has announced the addition of the "Global Chronic Kidney Disease (CKD) Drugs Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive...

KSPHF : 27.4271 (unch)
KERX : 6.93 (-0.29%)
JNJ : 135.97 (-0.27%)
AGN : 249.03 (+0.05%)
TEVA : 32.84 (-0.33%)
AMGN : 173.61 (-0.03%)
PFE : 33.92 (-0.35%)
Glaxo's (GSK) Shingles Candidate Phase III Data Positive

GlaxoSmithKline plc (GSK) announced positive top-line results from a phase III revaccination study on its shingles vaccine candidate, Shingrix, in older patients.

VVUS : 1.20 (+0.84%)
MRK : 65.92 (-0.21%)
TEVA : 32.84 (-0.33%)
GSK : 43.97 (-0.23%)
Erythropoietin (EPO) Drugs Market Forecast to 2025 - Analysis By Drug Class (Biologics, Biosimilars), Product (Epoetin-alfa, Epoetin-beta, Darbepoetin-alfa, Others), Application & Segment

Research and Markets has announced the addition of the "Erythropoietin (EPO) Drugs Market Analysis By Drug Class (Biologics, Biosimilars), By Product (Epoetin-alfa, Epoetin-beta, Darbepoetin-alfa, Others),...

JNJ : 135.97 (-0.27%)
TEVA : 32.84 (-0.33%)
AMGN : 173.61 (-0.03%)
Global Herpes Treatment Market to Grow at a CAGR of 12.9% by 2021 - Key Vendors are Gilead, GlaxoSmithKline, Merck & Novartis

Research and Markets has announced the addition of the "Global Herpes Treatment Market 2017-2021" report to their offering. The global herpes treatment market to grow at a CAGR of 12.97% during the period...

VICL : 2.50 (+0.81%)
MRK : 65.92 (-0.21%)
NVS : 86.08 (+0.38%)
TEVA : 32.84 (-0.33%)
GSK : 43.97 (-0.23%)
Injectable Drug Delivery Market, 2024

Research and Markets has announced the addition of the "Global Injectable Drug Delivery Market - Trends and Forecast to 2024" report to their offering. Global Injectable Drug Delivery Market is Expected...

TRUMF : 40.1300 (+1.61%)
LLY : 83.59 (-0.82%)
BAX : 60.78 (-0.33%)
TEVA : 32.84 (-0.33%)
ALKS : 57.75 (-0.94%)
PFE : 33.92 (-0.35%)
Technical Snapshots for These Drug Makers Stocks -- Endo, Teva Pharma, Ionis Pharma, and Amarin

Today, DailyStockTracker.com reviews Endo International PLC (NASDAQ: ENDP), Teva Pharmaceutical Industries Ltd (NYSE: TEVA), Ionis Pharmaceuticals Inc. (NASDAQ: IONS), and Amarin Corp. PLC (NASDAQ: AMRN)....

ENDP : 11.72 (-0.76%)
AMRN : 3.56 (+3.19%)
IONS : 54.60 (-1.62%)
TEVA : 32.84 (-0.33%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 48% Buy with a Average short term outlook on maintaining the current direction.

Longer term, the trend strength is Average. Long term indicators mostly agree with the trend.

The market is in highly overbought territory. Beware of a trend reversal.

See More

Business Summary

TEVA Pharmaceuticals USA, the business is to develop, manufacture, and market generic pharmaceuticals. Teva USA sells its products to chains, wholesalers, distributors, hospitals, managed care entities, and government agencies. The company markets a variety of dosage forms, including both extended...

See More

Support & Resistance

2nd Resistance Point 33.68
1st Resistance Point 33.32
Last Price 32.84
1st Support Level 32.68
2nd Support Level 32.40

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.